SCHEDULE 13G/A: BlackRock Discloses 4.97% Passive Stake in Utah Medical Products Inc.

BlackRock, Inc. has filed an updated Schedule 13G, reporting a 4.97% beneficial ownership stake in Utah Medical Products Inc. as of December 31, 2024, held for ordinary course of business purposes.

Summary

• BlackRock, Inc. reported beneficial ownership of 168,614 shares of Utah Medical Products Inc. common stock.
• This ownership represents 4.97% of the issuer's total outstanding common stock.
• The shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of Utah Medical Products Inc.
• BlackRock, Inc. holds sole voting power over 165,393 shares and sole dispositive power over 168,614 shares.
• No shared voting or dispositive power was reported by BlackRock, Inc. in this filing.
• The filing was made by BlackRock, Inc. as a parent holding company, aggregating holdings from various reporting business units.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) by a large institutional investor, BlackRock, Inc., indicating a passive stake below 5%. It contains no information that would suggest a positive or negative sentiment shift for the issuer, Utah Medical Products Inc.

Positives

• The disclosure of a significant institutional investor like BlackRock holding a stake, even if passive, can be viewed as a vote of confidence in the company.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Spencer Fleming, Managing Director of BlackRock, Inc.)

Industry Context

This is a standard disclosure for large institutional investors like BlackRock, which routinely hold passive stakes in numerous publicly traded companies as part of their asset management activities. It reflects a minor, non-controlling investment in a medical products company, consistent with typical institutional portfolio diversification.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake. No direct impact on share price or company operations is implied by this routine filing.
• Employees, Customers, Suppliers, Creditors: No direct impact from this beneficial ownership disclosure.

Key Dates

Keywords

BlackRock, Utah Medical Products Inc., Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment, medical products